Weïwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012;22(4):1822-6. doi:10.1016/j.bmcl.2011.09.047
Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378-384. doi:10.1038/nature21386
Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in -Mutant Cancers. Cold Spring Harb Perspect Med. 2018;8(8). doi:10.1101/cshperspect.a031518
Ladas I, Fitarelli-Kiehl M, Song C, et al. Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. Clin Chem. 2017;63(10):1605-1613. doi:10.1373/clinchem.2017.272849
Huarte M. Journal club. A biologist looks at new functions for non-coding RNAs. Nature. 2009;459(7246):487. doi:10.1038/459487e
Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 2005;37(1):48-55. doi:10.1038/ng1490
Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834-9. doi:10.1073/pnas.0806514106
Babij C, Zhang Y, Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011;71(17):5818-26. doi:10.1158/0008-5472.CAN-11-0778
Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25. doi:10.1158/2159-8290.CD-11-0046
Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158(1):171-84. doi:10.1016/j.cell.2014.06.004